Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Required: PIK3CA any tested

Only patients with PIK3CA/AKT1/PTEN alterations could include.

Required: AKT1 any tested

Only patients with PIK3CA/AKT1/PTEN alterations could include.

Required: PTEN any tested

Only patients with PIK3CA/AKT1/PTEN alterations could include.

Must have received: endocrine therapy — locally advanced or metastatic

Have received 1 to 2 prior lines of systemic treatments for LABC or mBC (at least one line was ET). If disease relapse during adjuvant therapy or relapse within 12 months from completion of adjuvant endocrine therapy, the adjuvant therapy will be counted as 1 line

Cannot have received: fulvestrant

Patients who had prior treatment with fulvestrant

Cannot have received: selective estrogen receptor degrader

Patients who had prior treatment with ... other selective estrogen receptor degraders (SERDs)

Cannot have received: PI3K inhibitor

Patients who had prior treatment with ... any PI3K/AKT/mTOR inhibitors

Cannot have received: AKT inhibitor

Patients who had prior treatment with ... any PI3K/AKT/mTOR inhibitors

Cannot have received: mTOR inhibitor

Patients who had prior treatment with ... any PI3K/AKT/mTOR inhibitors

Cannot have received: CDK4/6 inhibitor

Patients who had prior treatment with ... any CDK4/6 inhibitors in phase I, II study